13F Holdings
中文EN

CYAN CYANOTECH CORP

Medicinal Chemicals & Botanical Products · OTC · SEC CIK 768408 · Fiscal year ends 03/31

Financial factors as of 2025-09-30 (2025Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY8.5%
TTM net income YoY67.4%
TTM EPS YoY69.9%
Revenue 3-yr CAGR-5.0%
Net income 3-yr CAGR—

Margins

Gross margin32.0%
Operating margin-4.2%
Net margin-7.0%
FCF margin-5.7%
EBITDA margin1.5%

Returns

ROE-20.0%
ROA-7.4%
ROIC (approx.)-5.3%
Asset turnover1.05x

Leverage & solvency

Liabilities / assets66.4%
Debt / equity1.04x
Current ratio1.00x
Interest coverage-1.48x

Cash quality & payout

Operating cash flow / net income0.68x
Accruals ratio-2.4%
Payout ratio—
Capex / revenue0.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-03-31FY20242024-03-31FY20232023-03-31FY20222022-03-31FY20212021-03-31
Income statement
Revenue$24.21M$23.07M$23.18M$35.97M$32.34M
Cost of revenue$17.34M$17.13M$15.92M$22.40M$21.23M
Gross profit$6.88M$5.95M$7.26M$13.57M$11.12M
R&D expense$449,000$689,000$770,000$712,000$639,000
SG&A expense$4.40M$4.46M$4.66M$5.37M$4.88M
Operating income-$2.51M-$4.59M-$2.92M$2.57M$84,000
Interest expense$687,000$668,000$502,000$392,000$550,000
Pretax income-$3.19M-$5.26M-$3.42M$2.18M$923,000
Income tax$8,000$7,000$18,000$28,000$3,000
Net income-$3.20M-$5.27M-$3.44M$2.15M$920,000
EBITDA-$1.03M-$3.00M-$1.26M$4.17M$1.83M
EPS (basic)-0.45-0.81-0.550.350.15
EPS (diluted)—-0.81-0.550.350.15
Weighted avg. shares (diluted)—6,5316,2446,1686.08M
Balance sheet
Cash & equivalents$257,000$707,000$974,000$2.59M$3.77M
Receivables$1.95M$2.10M$1.33M$3.66M$2.44M
Inventory$7.79M$7.31M$10.71M$9.47M$8.41M
Current assets$10.54M$10.59M$13.50M$16.26M$15.11M
PP&E, net$8.93M$10.11M$11.37M$11.88M$12.14M
Total assets$23.49M$25.11M$29.73M$32.05M$30.88M
Current liabilities$10.24M$8.55M$8.10M$4.82M$5.81M
Short-term debt$6.65M$5.63M$5.41M$490,000$2.21M
Long-term debt$1.00M$1.00M$1.00M$4.34M$4.82M
Total debt$7.65M$6.63M$6.41M$4.83M$7.03M
Total liabilities$14.61M$13.30M$13.38M$12.56M$13.84M
Shareholders' equity$8.88M$11.81M$16.35M$19.49M$17.04M
Net debt$7.39M$5.92M$5.43M$2.24M$3.27M
Shares outstanding7.20M6.95M6.27M6.20M6.12M
Cash flow statement
Operating cash flow-$1.19M-$455,000-$2.10M$2.38M$2.40M
Capital expenditure$247,000$381,000$1.07M$1.27M$760,000
Free cash flow-$1.44M-$836,000-$3.17M$1.11M$1.64M
Investing cash flow-$247,000-$381,000-$1.07M-$1.27M-$760,000
Financing cash flow$990,000$569,000$1.55M-$2.29M-$290,000
Depreciation & amortization$1.48M$1.59M$1.66M$1.60M$1.75M
Stock-based compensation$247,000$359,000$310,000$344,000$214,000

Free plan shows the latest 5 periods; Pro shows all 16 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.